Tender detail
Non-exclusive discount agreement for medicines containing ezetimibe and atorvastatin
Summary
DAK-Gesundheit intends to conclude medicine discount agreements for products containing the active substances ezetimibe and atorvastatin (ATC C10BA05), excluding packs of 88 units. The agreement takes effect on 1 December 2026 and runs until 30 November 2028, with one possible 12-month extension. It ends automatically when an exclusive agreement takes effect.
More tender information after sign-in
The public view shows key tender details. Sign in to open official links, documents and AI tender support.